Drugmakers Push For Looser Off-Label Rules
Dangerously High Blood Glucose Levels Explained By Genetic Breakthrough
Prediabetes Can Be Reversed
Coversyl® Protects Hypertensive Patients Against New-Onset Diabetes
Aspirin for The Prevention of Diabetes
TZD’s Triple The Risk for Fracture
Regular Exercise In Middle Age Delays Aging By 12 Years
Possible New Therapy to Replenish Betacells Without Stemcells
Tight Blood Pressure Control Fails to Stall Kidney Disease in Blacks
Fenofibrate Does Not Halt Atherosclerosis in Patients With Diabetes
Impact of Metformin vs. Repaglinide on Cardiovascular Risk With Type 2’s
4 Steps to Reverse the Damage from Fast Food Diets
Study Ties Obesity, Inflammatory Proteins to Heart Failure Risk
Model Predicts Pill Combination Could Prevent 4.5 Million Deaths
Diabetes Education Reduces Hospitalizations
 
 

Preliminary results

 

GYM II STUDY (#16)

Efficacy of the diabetic supplement Gymnemosupium II, a combination of the extracts of Gymnema sylvestre, Pterocarpus marsupium, Diachrome and Vanadium administered to patients with Type 2 diabetes.  

 

Original Materials and Methods 

Each capsule of Gymnemosupium II is a proprietary formulation of Gymnema sylvestre,  75% standardized extract, Pterocarpus marsupium, 5% standardized extract, Diachrome,  a combination of chromium picolinate and biotin, and vanadium in the form of bis-glycinate oxo vanadium (BVOG). 

 

Each Type II diabetic will receive a total of 8 capsules of Gymnemosupium II a day administered in a four dose a day regiment, 2 capsules will be taken immediately before breakfast, lunch, supper and evening snack. The dose of 8 capsules a day will be maintained by doubling a dose if necessary if an individual dose is missed. 

Trial will continue for a period of 90 days utilizing a total of 48 Type II diabetic subjects ranging in age between 30 to 60 years old and currently have a hemoglobin A1c>8.0. 

Subjects must be free of any type of renal complication and also not be consuming more than 200mcg of chromium or 1mg of vanadium daily. All participants will give written informed consent and continue their normal diet, exercise routine and doses of oral hypoglycemic and insulin. Two weeks prior and throughout the trial daily morning fasting and supper postprandial blood glucose will be monitored.   

 

Hemoglobin A1c will be taken before administration of the Gymnemosupium II and immediately upon the conclusion of the study. Body weight and blood pressure will also be monitored in the beginning and at the close of the trial. All oral hypoglycemic and insulin doses will be recorded as well. Adverse side effects, if any, will be noted.   

 

First Data Results

 

A total of 18 patients have completed the 90 day study at this time.

 

For these 18 patients

 

Beginning A1c Average 8.75---- ranging from 9.7 to 7.8

Ending A1c Average 7.66---- ranging from 8.8 to 6.9

Average A1c improvement 1.08---- ranging from 2.7 to 0.4

 

In addition 2 patients so far, have reported increased Postprandial readings after product discontinuation due to completion of the study.

 

We are awaiting further data and will have a complete report in the near future, however early data reports indicate that Gym II is a safe and effective product

 

To read more about the ingredients click here http://www.diabetesincontrol.com/studies/gym2info.htm

 

Print This Page

 

 

 
 
Feature Categories
Downloads You Can Use
A. Lee Dellon, MD
Beverly Price
Birgitta I. Rice, MS
Did You Know
Dr. Bernstein
Dr. Brian Jakes, Jr.
Dr. Frank Varon, DDS
Dr. Fred Pescatore
Dr. Walter Willett
Education
Eric S. Freedland
Evan D. Rosen
Facts
Features
Ginger Kanzer-Lewis
Items for the Week
James Anderson, MD
Joseph M. Caporusso
Kristina Sandstedt
Laura Plunkett
Leonard Lipson, M.A.
Lester A. Packer
M. Teresa Volpone
Melissa Diane Smith
New Products
Newsflash
Paul Chous, M.A., OD
Philip A. Wood PhD
R. Keith Campbell
Sheri R. Colberg PhD
Sherri Shafer
Steve Pohlit
Studies
Test Your Knowledge
Theresa L. Garnero
Tools
Vickie R. Driver
Fast Food Carb Counter
Handle With Care: How To Throw Out Used Insulin Syringes and Lancets at Home
Guidelines for the Care of Students with Diabetes
Recipes for Better Living..
Diabetes in Control Glucose Flow Sheet
FACTS ABOUT Cholesterol
FACTS About Dietary Fats
Do You Know Your Quality of Life Number
Drugs That May Affect Blood Glucose Levels
DIC Newsletter Issue 217
DIC Newsletter Issue 218
DIC Newsletter Issue 219
DIC Newsletter Issue 100
DIC Newsletter Issue 101
DIC Newsletter Issue 102

Test Your Diabetes Knowledge
Test Your Knowledge Issue 415
Test Your Knowledge Issue 414
Test Your Knowledge Issue 413
Test Your Knowledge Issue 412
Test Your Knowledge Issue 411
Test Your Knowledge Issue 410
Test Your Knowledge Issue 409
Test Your Knowledge Issue 408
Test Your Knowledge Issue 407
Test Your Knowledge Issue 406
Test Your Knowledge Issue 405

Get the FREE Diabetes In Control Newsletter!

  • * Free Diabetes Related Information.
  • * Participation in Current and Future Studies
  • * Participation in Surveys (honorariums)
  • * Information that better helps your patients.
  • * Stay Current with the most updated information on treatments and medical devices.
  • * Learn about new studies......plus much more...

Simply Enter your Email Address Below to begin receiving the FREE Diabetes In Control Weekly Newsletter in your mailbox.
 

Please specify the format you can receive the newsletter in below

HTML Text AOL

Home · About Us · Advertise · Classifieds · Current News · Downloads · Education · Features · Feedback · Links · New Products · Past Newsletters · Recommend Us · Search · Show All Stories · Studies · Subscribe · Test Your Knowledge · Tools For Your Practice · Writers Archives · Search Our Archives · NewsFeed

We subscribe to the HONcode principles of the Health On the Net Foundation

©Copyright 1999-2003 Diabetes In Control

For Questions about this website click here